Methyl Aminolevulinate in Skin Cancers
Methyl aminolevulinate (MAL) is registered in several countries worldwide not only for PDT of actinic keratoses but also for superficial and nodular basal cell carcinoma (sBCC & nBCC) and Bowen’s disease. In the following chapter, evidence-based data of MAL-PDT for epithelial skin cancer are reviewed and further use of MAL-PDT is discussed. Cure rates for sBCC and nBCC are comparable to that of other nonsurgical procedures, whereas MAL-PDT for Bowen’s disease is as effective as conventional surgery or application of topical 5-FU or cryotherapy, but with much better cosmesis.
KeywordsCosmetic Outcome Actinic Keratose Nonmelanoma Skin Cancer Excellent Cosmetic Outcome Mohs Micrographic Surgery
- 4.Soler AM, Warloe T, Berner A, Giercksky KE. A follow-up study of recurrence and cosmesis in completely responding superficial and nodular basal cell carcinomas treated with methyl 5-aminolaevulinate-based photodynamic therapy alone and with prior curettage. Br J Dermatol. 2001;145:467–71.PubMedCrossRefGoogle Scholar
- 18.Pye A, Campbell S, Curnow A. Enhancement of methyl-aminolevulinate photodynamic therapy by iron chelation with CP94: an in vitro investigation and clinical dose-escalating safety study for the treatment of nodular basal cell carcinoma. J Cancer Res Clin Oncol. 2008;134:841–9.PubMedCrossRefGoogle Scholar